)
Sanuwave Health (SNWV) investor relations material
Sanuwave Health Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved record Q3 2025 revenue of $11.5 million, up 22% year-over-year and 13% sequentially, with strong UltraMIST system and consumable sales; 155 systems sold, bringing total field units to 1,416.
Net income for Q3 2025 was $10.3 million, reversing a $20.7 million loss in Q3 2024, driven by a $6.1 million non-cash gain from derivative liabilities and a $5 million patent sale.
Operating income for Q3 2025 was $1.5 million, down from $2.0 million in Q3 2024, mainly due to higher non-cash stock-based compensation.
Applicator/consumable revenue reached $6.8 million, up 26% year-over-year and 6% sequentially, representing 59% of total revenue.
Earnings per share (diluted) was $1.20, compared to a loss of $6.49 per share in Q3 2024.
Financial highlights
Gross margin improved to 77.9% in Q3 2025 from 75.5% a year ago, reflecting cost reductions and pricing initiatives.
Adjusted EBITDA for Q3 2025 was $3.5 million, up from $2.1 million in Q3 2024.
Cash and cash equivalents at quarter-end were $9.6 million; total current assets were $22.6 million.
Operating expenses increased year-over-year, mainly due to $1.4 million in stock-based compensation and higher headcount.
Interest expense declined 53% in Q3 2025, reflecting debt refinancing and note conversion to equity.
Outlook and guidance
Q4 2025 revenue guidance is $13–$14 million, representing 26–36% year-over-year growth; full-year 2025 revenue expected at $44–$45 million, up 35–39% over 2024.
Management believes recent debt refinancing and capital initiatives have alleviated substantial doubt about going concern for at least 12 months.
Plans to grow sales rep headcount and refine the mix between direct and distributor channels.
- TimeTickerHeadlineOpen
- BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - 032640
Net income surged 61.9% year-over-year, with strong wireless and enterprise growth. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue. - COHR
Q2 FY26 revenue up 17% to $1.69B, with strong EPS growth and robust datacenter demand. - ALGT
Q4 2025 saw record results and margin growth, with 2026 outlook boosted by Sun Country deal. - STC
Record bookings, strong cash flow, and margin expansion drive improved outlook.
Next Sanuwave Health earnings date
Next Sanuwave Health earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)